1Stampfer MJ, Colditz GA, Willett WC, et al. Postmenopausal estrogen therapy and cardiovascular disease.Ten-year follow-up from the nurses health study[J]. N Engl J Med, 1991, 325:756-762.
2Colvin PL JR, Auerbaeh BJ, Koritnik DR, et al. Differential effects of oral estrne versus 17 beta-estradiol on lipoproteins in postmenopausal women[J]. J Clin Endocrinol Metab, 1990, 70:1568-1573.
3Minnich A, Cllet X, Roghani A, et al. Site-direted mutagenesis and strueture-funetlon analysis of the humnan apolipoprotein A-I. Relation between lecithincholesterol acyltransferase activation and lipid binding[J]. Biol Chem, 1992, 267:16553-16560.
4Miller M. Current perspectives on the management of hypertriglyceridemia. Am Heart J, 2000,140: 232-240.
5Cole TG, Klotzsch SG, McNamara JR . Measurement of triglyceride concentration. In: Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of lipoprotein testing. Washington : AACC Press, 2000.207-219.
6Malloy MJ, Kane JP. A risk factor for atherosclerosis: triglyceride-rich lipoproteins. Adv Intern Med , 2001 , 47:111-136.
7Stein EA, Myers GL. National Cholesterol Education Program recommendations for triglyceride measurement: executive summary. Clin Chem , 1995,41:1427-1433.
8Holani KK, Miller WG, Waymack PP. Robustness of three triglyceride reagents for matrix effects of proficiency testing . Clin Chem , 1993,39:1126-1128.
9Klotzsch SG , McNamara JR . Triglyceride measurements: A review of methods and interferences. Clin Chem , 1990,36 : 1605-1613.
10Eberly LE, Stamler J, Neaton JD .Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med,2003,163:1077-1083.
